Outcomes with empagliflozin in heart failure with preserved ejection fraction using <scp>DELIVER</scp> ‐like endpoint definitions-Reference-Cited by-同舟云学术

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER ‐like endpoint definitions

Published:2022-06-05 Issue:8 Volume:24 Page:1400-1405
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Anker Stefan D.¹²,Siddiqi Tariq Jamal³,Filippatos Gerasimos⁴,Zannad Faiez⁵,Ferreira João Pedro⁵⁶,Pocock Stuart J.⁷,Brueckmann Martina⁸⁹,Zeller Cordula¹⁰,Packer Milton¹¹¹²,Butler Javed³¹¹

Affiliation:

1. Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin Berlin Germany

2. Institute of Heart Diseases Wrocław Medical University Wrocław Poland

3. Department of Medicine University of Mississippi School of Medicine Jackson MS USA

4. National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon Athens Greece

5. Université de Lorraine, Inserm, Centre d'Investigations Cliniques Plurithématique 1433, and Inserm U1116, CHRU, F‐CRIN INI‐CRCT Nancy France

6. Cardiovascular Research and Development Center, Department of Surgery and Physiology Faculty of Medicine of the University of Porto Porto Portugal

7. Department of Medical Statistics London School of Hygiene and Tropical Medicine London UK

8. Boehringer Ingelheim International GmbH Ingelheim Germany

9. First Department of Medicine, Faculty of Medicine Mannheim University of Heidelberg Mannheim Germany

10. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

11. Baylor Scott and White Research Institute Dallas TX USA

12. Imperial College London UK

Funder

Eli Lilly and Company

Boehringer Ingelheim

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2558

Reference5 articles.

1. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

2. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial

3. Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

4. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

5. AstraZeneca. Farxiga met primary endpoint in DELIVER Phase III trial reducing risk of cardiovascular death or worsening heart failurein patients with preserved ejection fraction.https://www.astrazeneca.com/media‐centre/press‐releases/2022/farxiga‐hfpef‐phase‐iii‐trial‐met‐primary‐endpoint.html[accessed on 16 May 2022].

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape;Heart Failure Reviews;2024-02-27

2. Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey;ESC Heart Failure;2023-08-02

3. August 2023 at a glance: Focus on epidemiology and medical therapy;European Journal of Heart Failure;2023-08

4. Expanded use of sodium‐glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-06-28

5. Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure;European Journal of Heart Failure;2023-05